Biocon Ltd. is aiming to become the world’s leading insulin supplier within the next five years, according to its Executive Chairperson and co-founder, Kiran Mazumdar-Shaw. The company plans to capitalize on rising global demand for insulin as major pharmaceutical companies increasingly shift their focus toward newer diabetes and weight-management therapies. Mazumdar-Shaw expressed confidence in Biocon’s ability to scale its insulin business globally. “In five years, we could be the number one insulin company in the world,” she said. “We are one of the few companies globally that has the scale to address that opportunity.”
Expanding Production Capacity to Meet Rising Demand
Biocon, manufacturer of generic medicines and biosimilars, has steadily strengthened its position in the global insulin market. Biosimilars are biological medicines that closely resemble branded biologic drugs while offering more affordable treatment options. The Bengaluru-based pharmaceutical company is currently the world’s third-largest insulin supplier by volume. To support future growth, Biocon has made substantial investments in expanding its manufacturing capacity and enhancing its supply capabilities. According to Mazumdar-Shaw, these investments are positioning the company to meet growing global demand for affordable insulin therapies.
Shifting Dynamics Create New Opportunities in the Insulin Market
Biocon’s ambitions come at a time when the global insulin market is undergoing significant transformation. The worldwide insulin market, estimated at approximately USD 30 billion, is witnessing a strategic shift as major pharmaceutical companies redirect resources toward next-generation metabolic therapies, particularly glucagon-like peptide-1 (GLP-1) drugs used for diabetes and obesity management.
Industry leaders such as Novo Nordisk and Eli Lilly, whose businesses were built on decades of insulin sales, are increasingly prioritizing newer diabetes and weight-loss treatments that offer stronger growth prospects and higher profitability. As a result, Biocon sees an opportunity to strengthen its presence in a segment that remains essential for millions of patients worldwide.
Growing Diabetes Burden Fuels Long-Term Insulin Demand
The need for insulin continues to rise globally. More than 830 million people are currently living with diabetes, and millions rely on insulin therapy to effectively manage their condition. Diabetes prevalence is increasing rapidly across emerging markets in Asia, Africa, and Latin America. Despite this growth, access to affordable insulin remains inconsistent in many regions. Healthcare advocates have expressed concerns that patients dependent on traditional insulin therapies could be overlooked as pharmaceutical companies focus heavily on next-generation treatments. Mazumdar-Shaw believes this evolving landscape presents a significant growth opportunity for Biocon. “The current situation is a windfall for me because I’m able to fill that gap, and my insulin business has just taken off,” she said.
Strategic Partnerships to Strengthen Global Reach
To accelerate expansion, Biocon is exploring partnerships across international markets. The company is particularly interested in collaborating with organizations that possess insulin pen and cartridge manufacturing capabilities. Through such alliances, Biocon aims to enhance production efficiency, expand market access, and strengthen its position as a reliable supplier of insulin products worldwide.
Taking a Cautious Approach to the GLP-1 Market
While many pharmaceutical companies are aggressively pursuing opportunities in the rapidly growing obesity and diabetes drug segment, Biocon is adopting a more measured strategy. The expiration of patents covering semaglutide—the active ingredient in blockbuster drugs such as Wegovy and Ozempic—has opened the door for generic manufacturers worldwide. Countries including India and Canada are already witnessing the entry of lower-cost alternatives. However, Mazumdar-Shaw believes the generic GLP-1 market is becoming increasingly crowded. “We have to be aware that generic GLP-1s is a crowded market,” she said. “Being a generics player, we are realistic about the level of global competition.”
Selective Market Focus for Future GLP-1 Opportunities
Biocon does not currently plan to launch generic semaglutide products in India, where intense competition has already driven prices sharply downward. Instead, the company intends to pursue opportunities selectively in international markets where growth prospects and pricing dynamics are more favourable. Mazumdar-Shaw identified Canada, Latin America, Brazil, the Middle East, and Southeast Asia as regions where Biocon sees meaningful opportunities for GLP-1 therapies.
Building a Sustainable Growth Strategy
Rather than chasing every emerging opportunity, Biocon is balancing investments between its rapidly expanding insulin business and carefully targeted participation in the GLP-1 segment. By leveraging its manufacturing scale, biosimilar expertise, and global partnerships, the company aims to strengthen its leadership in diabetes care while creating a sustainable growth platform for the future. As reported by thehindubusinessline.com, as the global diabetes burden continues to rise, Biocon’s strategy positions it to play an increasingly important role in delivering affordable and accessible therapies to patients worldwide.
